Edgewise Therapeutics
EWTX | NASDAQ
$43.68
-$2.25 (-4.90%)
At close: Nov 16, 2026, 4:00 PM ET
$43.68
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Edgewise Therapeutics Company Profile
Company profile explainedCompany Profile
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Key Executives
| Name | Position |
|---|---|
| Kevin Koch | President, Chief Executive Officer & Director |
| Behrad Derakhshan | Chief Operating Officer |
| Michael Nofi | Chief Financial Officer |
| Alan J. Russell | Co-Founder, Chief Scientific Officer & Director |
| Aylin Tugcu | Senior Vice President of Cardiovascular Clinical Development & Medical Affairs |
| Badreddin Edris | Co-Founder & Independent Director |
| Joanne Donovan | Chief Medical Officer |
| John R. Moore | General Counsel |
| Peter A. Thompson FACP | Co-Founder & Independent Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 4 | Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 17, 2026 | 4/A | [Amend] Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
Edgewise Therapeutics
| Country | United States |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Kevin Koch |
Contact Details
1715 38th Street Boulder,
Colorado 80301 United States
Stock Details
| Ticker Symbol | EWTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001710072 |
| CUSIP Number | 28036F105 |
| ISIN Number | US28036F1057 |
| SIC Code | 2834 |
Recent News
- 8 days ago / prnewswire.comEdgewise Therapeutics to Participate in Upcoming Investor Conferences
- 12 days ago / prnewswire.comEdgewise Therapeutics Reports Third Quarter 2026 Financial Results
- 1 month ago / prnewswire.comEdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
- 2 months ago / seekingalpha.comEdgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
- 2 months ago / prnewswire.comEdgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
- 3 months ago / prnewswire.comEdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
- 3 months ago / seekingalpha.comEdgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
- 3 months ago / prnewswire.comEdgewise Therapeutics Reports Second Quarter 2026 Financial Results
- 4 months ago / prnewswire.comEdgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
- 5 months ago / seekingalpha.comEdgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Add to Watchlist
Select watchlists to add or remove EWTX